Protagonist Therapeutics (PTGX) Share-based Compensation (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Share-based Compensation data on file, last reported at $14.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 5.19% year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.2 million (up 6.66% YoY), and the FY2025 full-year result was $78.0 million, up 37.08% from the prior year.
• Share-based Compensation improved to $14.5 million in Q1 2026, from -$11.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.5 million in Q1 2026 to a low of -$18.0 million in Q4 2024.
• A 5-year average of $1.5 million and a median of $2.6 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 3340.14% in 2023 and soared 1080.31% in 2024, its largest moves.
• Tracing PTGX's Share-based Compensation over 5 years: stood at $553000.0 in 2022, then sank by 3340.14% to -$17.9 million in 2023, then slipped by 0.18% to -$18.0 million in 2024, then soared by 33.54% to -$11.9 million in 2025, then soared by 221.7% to $14.5 million in 2026.
• Business Quant data shows PTGX's Share-based Compensation at $14.5 million in Q1 2026, -$11.9 million in Q4 2025, and $5.7 million in Q3 2025.